Alaunos Therapeutics (TCRT) Competitors $3.19 -0.25 (-7.27%) Closing price 04:00 PM EasternExtended Trading$3.19 0.00 (0.00%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. CING, LSTA, AYTU, APLM, HOTH, EDSA, CLRB, SYBX, FNCH, and ASBPShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Cingulate (CING), Lisata Therapeutics (LSTA), Aytu BioPharma (AYTU), Apollomics (APLM), Hoth Therapeutics (HOTH), Edesa Biotech (EDSA), Cellectar Biosciences (CLRB), Synlogic (SYBX), Finch Therapeutics Group (FNCH), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Its Competitors Cingulate Lisata Therapeutics Aytu BioPharma Apollomics Hoth Therapeutics Edesa Biotech Cellectar Biosciences Synlogic Finch Therapeutics Group Aspire Biopharma Cingulate (NASDAQ:CING) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Do insiders & institutionals believe in CING or TCRT? 41.3% of Cingulate shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 4.0% of Cingulate shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer CING or TCRT? Cingulate currently has a consensus price target of $27.75, indicating a potential upside of 593.75%. Given Cingulate's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cingulate is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is CING or TCRT more profitable? Alaunos Therapeutics' return on equity of -168.02% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -232.16% -132.07% Alaunos Therapeutics N/A -168.02%-121.37% Which has stronger earnings and valuation, CING or TCRT? Alaunos Therapeutics has higher revenue and earnings than Cingulate. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$15.55M-$4.10-0.98Alaunos Therapeutics$6K1,172.86-$4.68M-$2.46-1.30 Which has more risk and volatility, CING or TCRT? Cingulate has a beta of -0.75, suggesting that its share price is 175% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500. Does the media favor CING or TCRT? In the previous week, Cingulate had 9 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 11 mentions for Cingulate and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.96 beat Cingulate's score of 0.12 indicating that Alaunos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cingulate Neutral Alaunos Therapeutics Positive SummaryCingulate and Alaunos Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.04M$2.62B$6.05B$10.51BDividend YieldN/A57.77%5.73%4.80%P/E Ratio-1.3022.7985.3627.35Price / Sales1,172.86557.62516.10196.40Price / CashN/A174.0137.5761.53Price / Book2.475.5112.426.82Net Income-$4.68M$33.06M$3.32B$276.80M7 Day Performance-13.78%0.96%0.97%0.26%1 Month Performance41.78%14.26%10.70%8.29%1 Year Performance44.34%0.86%76.19%35.59% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics1.1983 of 5 stars$3.19-7.3%N/A+65.4%$7.04M$6K-1.3040Analyst ForecastGap DownCINGCingulate2.5421 of 5 stars$4.15+1.5%$26.25+532.5%-8.0%$22.14MN/A-1.0120News CoverageAnalyst ForecastLSTALisata Therapeutics2.5994 of 5 stars$2.47-1.6%$23.50+851.4%-17.1%$21.98M$1M-1.1130Gap DownAYTUAytu BioPharma3.6393 of 5 stars$2.36+7.8%$9.17+288.4%+5.3%$21.71M$66.38M-0.84160Analyst ForecastGap UpHigh Trading VolumeAPLMApollomics0.7995 of 5 stars$18.43+51.3%N/A+34.5%$20.34M$1.49M0.0045Trending NewsTrading HaltedHigh Trading VolumeHOTHHoth Therapeutics1.9306 of 5 stars$1.53flat$4.00+161.4%+87.8%$20.29MN/A-1.434EDSAEdesa Biotech3.1911 of 5 stars$2.75-4.5%$5.00+81.8%-41.5%$20.27MN/A-2.0820News CoverageCLRBCellectar Biosciences2.1895 of 5 stars$5.13-16.9%$375.00+7,209.9%-92.0%$19.69MN/A-0.2610High Trading VolumeSYBXSynlogic0.7098 of 5 stars$1.70+1.3%N/A+22.1%$19.58M$10K-21.1980FNCHFinch Therapeutics GroupN/A$12.03-0.8%N/A+3.9%$19.32MN/A-1.36190ASBPAspire BiopharmaN/A$0.36-6.7%N/AN/A$19.06MN/A0.00N/A Related Companies and Tools Related Companies Cingulate Alternatives Lisata Therapeutics Alternatives Aytu BioPharma Alternatives Apollomics Alternatives Hoth Therapeutics Alternatives Edesa Biotech Alternatives Cellectar Biosciences Alternatives Synlogic Alternatives Finch Therapeutics Group Alternatives Aspire Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
